210 related articles for article (PubMed ID: 22918682)
1. Readressing the role of Toll-like receptor-4 alleles in inflammatory bowel disease: colitis, smoking, and seroreactivity.
Manolakis AC; Kapsoritakis AN; Kapsoritaki A; Tiaka EK; Oikonomou KA; Lotis V; Vamvakopoulou D; Davidi I; Vamvakopoulos N; Potamianos SP
Dig Dis Sci; 2013 Feb; 58(2):371-80. PubMed ID: 22918682
[TBL] [Abstract][Full Text] [Related]
2. Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course.
Paul S; Boschetti G; Rinaudo-Gaujous M; Moreau A; Del Tedesco E; Bonneau J; Presles E; Mounsef F; Clavel L; Genin C; Flourié B; Phelip JM; Nancey S; Roblin X
J Crohns Colitis; 2015 Jun; 9(6):445-51. PubMed ID: 25895876
[TBL] [Abstract][Full Text] [Related]
3. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
Papp M; Altorjay I; Dotan N; Palatka K; Foldi I; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Norman GL; Szamosi T; Papp J; ; Lakatos PL
Am J Gastroenterol; 2008 Mar; 103(3):665-81. PubMed ID: 18047543
[TBL] [Abstract][Full Text] [Related]
4. Genetic association and phenotypic correlation of TLR4 but not NOD2 variants with Tunisian inflammatory bowel disease.
Feki S; Bouzid D; Abida O; Chtourou L; Elloumi N; Toumi A; Hachicha H; Amouri A; Tahri N; Masmoudi H
J Dig Dis; 2017 Nov; 18(11):625-633. PubMed ID: 29055077
[TBL] [Abstract][Full Text] [Related]
5. α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease.
Manolakis AC; Christodoulidis G; Kapsoritakis AN; Georgoulias P; Tiaka EK; Oikonomou K; Valotassiou VJ; Potamianos SP
World J Gastroenterol; 2017 Jan; 23(3):437-446. PubMed ID: 28210079
[TBL] [Abstract][Full Text] [Related]
6. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis.
Franchimont D; Vermeire S; El Housni H; Pierik M; Van Steen K; Gustot T; Quertinmont E; Abramowicz M; Van Gossum A; Devière J; Rutgeerts P
Gut; 2004 Jul; 53(7):987-92. PubMed ID: 15194649
[TBL] [Abstract][Full Text] [Related]
7. [Toll-like receptor gene polymorphisms and susceptibility to inflammatory bowel disease in Chinese Han and Caucasian populations].
Shen XY; Shi RH; Wang Y; Zhang HJ; Zhou XQ; Shen FC; Li KB
Zhonghua Yi Xue Za Zhi; 2010 May; 90(20):1416-20. PubMed ID: 20646633
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease.
Rigoli L; Romano C; Caruso RA; Lo Presti MA; Di Bella C; Procopio V; Lo Giudice G; Amorini M; Costantino G; Sergi MD; Cuppari C; Calabro GE; Gallizzi R; Salpietro CD; Fries W
World J Gastroenterol; 2008 Jul; 14(28):4454-61. PubMed ID: 18680223
[TBL] [Abstract][Full Text] [Related]
9. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population.
Gazouli M; Mantzaris G; Kotsinas A; Zacharatos P; Papalambros E; Archimandritis A; Ikonomopoulos J; Gorgoulis VG
World J Gastroenterol; 2005 Feb; 11(5):681-5. PubMed ID: 15655821
[TBL] [Abstract][Full Text] [Related]
10. Higher titers of anti-Saccharomyces cerevisiae antibodies IgA and IgG are associated with more aggressive phenotypes in Romanian patients with Crohn's disease.
Gologan S; Iacob R; Preda C; Vadan R; Cotruta B; Catuneanu AM; Iacob S; Constantinescu I; Gheorghe L; Iobagiu S; Gheorghe C; Diculescu M
J Gastrointestin Liver Dis; 2012 Mar; 21(1):39-44. PubMed ID: 22457858
[TBL] [Abstract][Full Text] [Related]
11. Association between toll-like receptors/CD14 gene polymorphisms and inflammatory bowel disease in Korean population.
Kim EJ; Chung WC; Lee KM; Paik CN; Jung SH; Lee BI; Chae HS; Choi KY
J Korean Med Sci; 2012 Jan; 27(1):72-7. PubMed ID: 22219617
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases.
Pierik M; Joossens S; Van Steen K; Van Schuerbeek N; Vlietinck R; Rutgeerts P; Vermeire S
Inflamm Bowel Dis; 2006 Jan; 12(1):1-8. PubMed ID: 16374251
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-17 serum levels and TLR4 polymorphisms in ulcerative colitis.
Mohammadi M; Zahedi MJ; Nikpoor AR; Baneshi MR; Hayatbakhsh MM
Iran J Immunol; 2013 Jun; 10(2):83-92. PubMed ID: 23811547
[TBL] [Abstract][Full Text] [Related]
14. MAGI2 genetic variation and inflammatory bowel disease.
McGovern DP; Taylor KD; Landers C; Derkowski C; Dutridge D; Dubinsky M; Ippoliti A; Vasiliauskas E; Mei L; Mengesha E; King L; Pressman S; Targan SR; Rotter JI
Inflamm Bowel Dis; 2009 Jan; 15(1):75-83. PubMed ID: 18720471
[TBL] [Abstract][Full Text] [Related]
15. Serum antibodies associated with complex inflammatory bowel disease.
Elkadri AA; Stempak JM; Walters TD; Lal S; Griffiths AM; Steinhart AH; Silverberg MS
Inflamm Bowel Dis; 2013 Jun; 19(7):1499-505. PubMed ID: 23702714
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?
Fernandes P; MacSharry J; Darby T; Fanning A; Shanahan F; Houston A; Brint E
Clin Exp Immunol; 2016 Mar; 183(3):358-68. PubMed ID: 26462859
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
Sipeki N; Davida L; Palyu E; Altorjay I; Harsfalvi J; Szalmas PA; Szabo Z; Veres G; Shums Z; Norman GL; Lakatos PL; Papp M
World J Gastroenterol; 2015 Jun; 21(22):6952-64. PubMed ID: 26078573
[TBL] [Abstract][Full Text] [Related]
18. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.
Papp M; Altorjay I; Norman GL; Shums Z; Palatka K; Vitalis Z; Foldi I; Lakos G; Tumpek J; Udvardy ML; Harsfalvi J; Fischer S; Lakatos L; Kovacs A; Bene L; Molnar T; Tulassay Z; Miheller P; Veres G; Papp J; ; Lakatos PL
Inflamm Bowel Dis; 2007 Aug; 13(8):984-92. PubMed ID: 17417801
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms: New data and a meta-analysis.
Senhaji N; Diakité B; Serbati N; Zaid Y; Badre W; Nadifi S
BMC Gastroenterol; 2014 Dec; 14():206. PubMed ID: 25492126
[TBL] [Abstract][Full Text] [Related]
20. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
